Syros Pharmaceuticals, Inc. (SYRS)
Develops drugs to treat blood cancers and leukemia
$0.00+0.00%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-93.8%
The outlook
SYRS trades at its 52-week low with price well below both short and long-term moving averages. Analyst targets suggest substantial upside versus the current level, though coverage context is limited. Overall sentiment leans bearish based on current technical positioning.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range0% of the way from its 52-week low to high
Price targetAvg target +8749900% vs current price
Analyst price target
~12-month · 4 analysts$8.75average target+8749900.0% vs now
Now $0.00
Low $4.00High $20.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$2,683
52-wk high
$0.02
52-wk low
$0.00
50-day avg
$0.00
200-day avg
$0.00
Trailing P/E
—